This article has Open Peer Review reports available.
A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: The AIO KRK 0110 Trial/ML22011 Trial
- Clemens Giessen1,
- Ludwig Fischer von Weikersthal2,
- Axel Hinke3,
- Sebastian Stintzing1,
- Frank Kullmann4,
- Ursula Vehling-Kaiser5,
- Julia Mayerle6,
- Markus Bangerter7,
- Claudio Denzlinger8,
- Markus Sieber9,
- Christian Teschendorf10,
- Jens Freiberg-Richter11,
- Christoph Schulz1,
- Dominik Paul Modest1,
- Nicolas Moosmann1,
- Philipp Aubele1 and
- Volker Heinemann1Email author
© Giessen et al.; licensee BioMed Central Ltd. 2011
Received: 28 March 2011
Accepted: 23 August 2011
Published: 23 August 2011
Open Peer Review reports
Pre-publication versions of this article and author comments to reviewers are available by contacting firstname.lastname@example.org.
|28 Mar 2011||Submitted||Original manuscript|
|5 Jul 2011||Reviewed||Reviewer Report - Stephen Clarke|
|29 Jul 2011||Author responded||Author comments - Clemens Giessen|
|Resubmission - Version 2|
|29 Jul 2011||Submitted||Manuscript version 2|
|20 Aug 2011||Author responded||Author comments - Clemens Giessen|
|Resubmission - Version 3|
|20 Aug 2011||Submitted||Manuscript version 3|
|23 Aug 2011||Editorially accepted|
|23 Aug 2011||Article published||10.1186/1471-2407-11-367|
How does Open Peer Review work?
Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article and author comments to reviewers are available by contacting email@example.com. All previous versions of the manuscript and all author responses to the reviewers are also available.
You can find further information about the peer review system here.